

---

# Kluwer Patent Blog

## Lundbeck / Tiefenbacher, Ratiopharm, Teva Pharma, Court of Appeal Brussels (Hof van Beroep te Brussel), 14 February 2012

Florence Verhoestraete · Sunday, October 14th, 2012 · Landmark European Patent Cases

The Court of Appeal partially reversed the Brussels Commercial Court's decision invalidating Lundbeck's SPC for escitalopram, to the extent that it had immediate effect.

A summary of this case will be posted on <http://www.KluwerIPCases.com>

---

*To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please [subscribe here](#).*

### Kluwer IP Law

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how **Kluwer IP Law** can support you.

---

79% of the lawyers think that the importance of legal technology will increase for next year.

**Drive change with Kluwer IP Law.**

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT  
The Wolters Kluwer Future Ready Lawyer  
Leading change

This entry was posted on Sunday, October 14th, 2012 at 10:33 am and is filed under [Belgium](#), [Case Law](#), [Pharma](#), [SPC](#), [Validity](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.